OR WAIT null SECS
Evogen and LGC have signed a worldwide licence agreement, which will allow Evogen to augment its rapid molecular diagnostics and detection platform with LGC?s HyBeacons PCR probe chemistry technology.
Evogen and LGC have signed a worldwide licence agreement, which will allow Evogen to augment its rapid molecular diagnostics and detection platform with LGC’s HyBeacons PCR probe chemistry technology. This licence gives Evogen exclusive and sub-licensable rights to the HyBeacons technology within its key market areas.
"The addition of LGC’s HyBeacons technology to the EvoCycler platform substantially increases the performance of the assays that we will be providing to the clinical, environmental and biodefence markets," said Sean Reineke, Evogen’s president and CEO.
John McQuillian, LGC’s director of life and food sciences is pleased with the agreement; "The potential opportunities created by combining our cutting-edge HyBeacons technology with the Evogen platform and technologies are extremely exciting. This combination will bring our probe chemistry into many more laboratories and point-of-use locations. We anticipate that the HyBeacons assay menu will expand quickly in the near future through the joint efforts of Evogen, LGC and our expanding network of partnerships."
Additionally, Evogen expect to be able to offer an expanding menu of molecular diagnostics tests for clinical, biodefence and environmental applications using HyBeacons chemistry. Along with test kits and instruments, future product offerings will include peripherals that will enable the streamlining of the testing process in a variety of complex settings.
For more on Evogen, visit the company’s website at www.evogen.com
Visit the LGC website at www.lgc.co.uk